Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marker TherapeuticsFRA:GX1 -5.26%32 Cyclically Adjusted PB Ratio is 0.24 as of Aug. 15, 2026, which is 99% below its 10-year median of 17.91. GuruFocus rates FRA:GX1 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 692 Biotechnology companies, Marker Therapeutics ranks better than 82.95% on this metric.
The historical rank and industry rank for Marker Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:GX1'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.24 Med: 17.91 Max: 54.06
Current: 0.24
During the past years, Marker Therapeutics's highest Cyclically Adjusted PB Ratio was 54.06. The lowest was 0.24. And the median was 17.91.
FRA:GX1's Cyclically Adjusted PB Ratio is ranked better than 82.95% of 692
companies
in the Biotechnology industry
Industry Median: 1.62
vs FRA:GX1: 0.24
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Marker Therapeutics's adjusted book value per share data for the three months ended in Mar. 2026 was €0.716. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.38 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Marker Therapeutics (FRA:GX1) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Marker Therapeutics Cyclically Adjusted PB Ratio Related Terms
Marker Therapeutics Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Marker Therapeutics's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marker Therapeutics Cyclically Adjusted PB Ratio Chart
FRA:GX1 vs NCEL, HOWL, CVM: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Marker Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Marker Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Marker Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Marker Therapeutics's Cyclically Adjusted PB Ratio falls into.
Marker Therapeutics Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Marker Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 0.24 mean?
Marker Therapeutics (FRA:GX1) has a Cyclically Adjusted PB Ratio of 0.24 as of Aug. 15, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Marker Therapeutics and its competitors. This is 99% below median its historical median of 17.91. Over the past decade, Marker Therapeutics' Cyclically Adjusted PB Ratio has ranged from 0.24 to 54.06. According to the industry distribution chart, Marker Therapeutics ranks #118 out of 692 companies in the Biotechnology industry, placing it in the top 17.1%.
Is Marker Therapeutics' Cyclically Adjusted PB Ratio too high?
Marker Therapeutics' current Cyclically Adjusted PB Ratio of 0.24 is 99% below median its 10-year median of 17.91. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 54.06. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Marker Therapeutics' value of 0.24 is 85.2% below this industry median. Based on the distribution chart, Marker Therapeutics ranks #118 out of 692 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Marker Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Marker Therapeutics' Cyclically Adjusted PB Ratio compare to NCEL and HOWL?
According to the Biotechnology industry distribution chart, Marker Therapeutics ranks #118 out of 692 companies for Cyclically Adjusted PB Ratio. This places Marker Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Cyclically Adjusted PB Ratio is 1.62. Marker Therapeutics' value of 0.24 is 85.2% below this benchmark. Historically, Marker Therapeutics' own Cyclically Adjusted PB Ratio has ranged from 0.24 to 54.06 over the past decade. While the company's 10-year median is 17.91 vs. the industry median of 1.62, Marker Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Marker Therapeutics's current Cyclically Adjusted PB Ratio of 0.24 is 85.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Marker Therapeutics and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marker Therapeutics's current Cyclically Adjusted PB Ratio is 0.24, which is 99% below median its own 10-year median of 17.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marker Therapeutics stock overvalued right now?
Marker Therapeutics (FRA:GX1) has a current Cyclically Adjusted PB Ratio of 0.24. The current Cyclically Adjusted PB Ratio is 0.24, which is 99% below median its 10-year median of 17.91 and 85.2% below the Biotechnology industry median of 1.62. Marker Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Marker Therapeutics (FRA:GX1), the current Cyclically Adjusted PB Ratio is 0.24 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
32GF Score
Get the complete analysis for FRA:GX1
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GX1 has been successfully added to your 
